Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +336.08%
#4 aPriori aPriori +187.76%
#5 Bedrock Bedrock +78.72%
#6 Cysic Cysic +52.73%
#7 Prom Prom +43.01%
#8 Playnance Playnance +34.94%
#9 Bitway Bitway +27.98%
#10 COTI COTI +25.34%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Midatech Pharma plc Midatech Pharma plc

Midatech Pharma plc

MTPH
Rank in Stocks #42756
Midatech Pharma plc operates as a pharmaceutical company specializing in drug... Midatech Pharma plc operates as a pharmaceutical company specializing in drug delivery technologies. Its core activities revolve around the research and development of therapeutic compounds, with operations spanning the United Kingdom, broader Europe, and global markets. Currently, its pipeline includes several key developments: MTX110, an innovative direct-delivery therapy targeting diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immunosuppressant designed for topical use against psoriasis; MTD211, a sustained-release version of brexpiprazole intended for managing schizophrenia and as an add-on therapy for major depressive disorder; and MTD219, a prolonged-action formulation of tacrolimus aimed at reducing the likelihood of organ transplant rejection. Beyond its specific drug candidates, Midatech Pharma provides advanced drug delivery platforms. These include Q-Sphera, a microtechnology based on polymer microspheres that enables drugs to be released over extended periods; MidaSolve, a nanotechnology employing oligosaccharides to enhance drug solubility, allowing direct and localized administration into tumors; and MidaCore, a gold nanoparticle system engineered to precisely deliver chemotherapeutic or immunotherapeutic agents to disease sites. Established in 2000, the company maintains its headquarters in Cardiff, United Kingdom.
Share Price
$0.05309195
Last synced: 2023-04-24
Market Cap
$164.43
Change (1 day)
0.46%
Change (1 year)
0.00%
Country
GB
Trade Midatech Pharma plc (MTPH)

Category

Healthcare
P/E ratio for Midatech Pharma plc (MTPH)
P/E ratio as of 2026 TTM: 0
According to Midatech Pharma plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Midatech Pharma plc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.